Researchers at Weill Cornell Medicine and Roswell Park Comprehensive Cancer Center reported preclinical results supporting intravesical delivery of MUC16-targeting CAR T cells to control bladder cancer growth. In work published in the Journal of Experimental Medicine, the team engineered CAR T cells that target the clinically relevant antigen MUC16 and demonstrated that direct delivery into the bladder via catheter can control tumors in mice. The authors frame the approach as an easier-to-implement, potentially more effective strategy than systemic CAR T delivery routes that face solid-tumor barriers. With bladder cancer’s high recurrence and progression burden, the study adds another pipeline direction focused on local immunotherapy delivery to improve efficacy and reduce off-target toxicities.